AstraZeneca Results Presentation Deck

AstraZeneca in Breast Cancer Ambition to eliminate breast cancer as a cause of death Est. epi (G7) Low risk HR-positive Intermediate / high risk HR-positive Neoadjuvant Potential for ADCs to replace chemo Early 405k Adjuvant Current SoC drives good outcomes for patients with low risk HR-positive eBC Low unmet need and limited opportunity to add benefit Camizestrant to replace ET CTX → camizestrant (+/- CDK4/6i) CAMBRIA-2 CTX → AI (+/- CDK4/6i) 2-5 yrs → camizestrant CAMBRIA-1 CRURENCE RECRU ET benefit from HR+ mBC Less 1st line 80k Camizestrant to replace ET ESR1m camizestrant + CDK4/6i SERENA-4 AI + CDK4/6i → camizestrant + CDK4/6i SERENA-6 Improve upon CDK4/6i + ET capivasertib + Faslodex + CDK4/6i CAPItello292 current ET Loss of clinical benefit to 1 1 2nd line 65k Metastatic Address ET + CDK4/6i resistance capivasertib + Faslodex CAPItello291 Replace chemotherapy APPENDIX | Oncology tumour maps Enhertu DESTINY-Breast06 HER2-low 0-1+, 1+, 2+ 3rd line 55k Loss of clinical benefit to current ET 4th line + 50k Replace chemotherapy Dato-DXd TROPION-Breast01 Replace chemotherapy Enhertu DESTINY-Breast04 HER2-low 1+, 2+ All numbers are approximate. Illustrative settings and populations, not to scale. HR = hormone receptor; est epi (G7) = estimated epidemiology across G7 (US, EU5, JP for drug treated patients; SoC = standard of care; ADC = antibody drug conjugate; ET = endocrine therapy; CTx = chemotherapy; Al = aromatase inhibitor; CDK4/6i = cyclin- 37 dependent kinase 4 and 6 inhibitor; yrs = years; ESR1m = estrogen receptor 1 gene mutation; ER = estrogen receptor; Dato-DXd = datopotamab deruxtecan. Collaboration partners: Daiichi Sankyo (Enhertu, Dato-DXd). 4

View entire presentation